After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
AMGN is neutral now, but a close below $158 weakens the chart picture.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.
Stock losses accelerate on Thursday as Deutsche Bank and Wells Fargo drag on the financials sector.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.